Clinical trials: Treatment Endometrial Cancer
Endometrial Cancer
ctDNA Assessment in Endometrial Cancer for Adjuvant Therapy
The goal of this observational study is to evaluate whether combining postoperative circulating tumor DNA (ctDNA) testing with a novel genomic risk model can better predict recurrence risk and guide adjuvant therapy decisions in…
- Trial name
- NCT07681414
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Guizhou Provincial People's Hospital
Non Small Cell Lung Cancer, Cervical Cancer
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor activity of XB002 administered IV q3w alone and in combination with…
- Conditions
- Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer
- Trial name
- NCT04925284
- Testing
- XB002, Nivolumab, Bevacizumab
- Where
- 95 sites in United States, Australia and 7 more
- Volunteers
- 269 people
- Sponsor
- Exelixis
Polycystic Ovary Syndrome, Anovulatory
Endometrial Thickness and Subendometrial Vascularity in Anovulatory Polycystic Ovarian Syndrome Patients Treated by Metformin
The participants will receive metformin 500mg 3times per day for 3months and one month is left for spontaneous pregnancy to occur or not (primary outcome ) and the investigators will check endometrial thickness and…
- Trial name
- NCT03486626
- Testing
- Metformin
- Where
- Egypt
- Volunteers
- 85 people
- Sponsor
- Ain Shams Maternity Hospital
Endometrial Cancer
An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation
Multicenter, observational, prospective study of molecular profiling in advanced and aggressive endometrial cancer patients and 1-st line treatment approaches in Russian Federation
- Trial name
- IREN (NCT07041606)
- Where
- 19 sites in Russia
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Endometrial Carcinoma Stage I
Megestrol Acetate Plus Rosuvastatin in Young Women With Early Endometrial Carcinoma
To explore the treatment efficacy of megestrol acetate plus rosuvastatin in patients with early endometrial carcinoma (EEC) seeking for conservative treatment.
- Trial name
- NCT04491643
- Testing
- Megestrol Acetate, Rosuvastatin
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Fudan University
Genital Neoplasms, Female, Uterine Cervical Neoplasms
Patient Journey in Advanced Gynecologic Cancers
This is a mixed-methods survey study including a 2-phased sequential-explanatory design. This study is to understand the patient journey in conventional therapy for newly diagnosed stage III or IV CC or EC in China, including…
- Conditions
- Genital Neoplasms, Female, Uterine Cervical Neoplasms, Endometrial Carcinoma
- Trial name
- NCT07015593
- Testing
- interview
- Where
- 4 sites in China
- Volunteers
- 780 people
- Sponsor
- Tongji Hospital
Endometrial Carcinoma, Metastatic Carcinoma
Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)
The investigators hypothesize that the dual inhibition of mTORC1/mTORC2 by AZD2014 combined with inhibition of aromatase enzyme by anastrozole will act synergistically and may be an interesting therapeutic option for endometrial…
- Conditions
- Endometrial Carcinoma, Metastatic Carcinoma, Hormone Receptor Positive Tumor
- Trial name
- VICTORIA (NCT02730923)
- Testing
- AZD2014, Anastrozole
- Where
- 12 sites in France
- Volunteers
- 72 people
- Sponsor
- Centre Leon Berard
Advanced or Recurrent Endometrial Cancer
Efficacy Study of Chemotherapy to Treat Advanced or Recurrent Endometrial Cancer
The purpose of this study is to treat advanced or recurrent endometrial cancer, paclitaxel-containing regimen is the preferred chemotherapeutic regimen which is selected by most physicians.
- Trial name
- NCT01461759
- Testing
- Doctaxel, Cisplatin
- Where
- South Korea
- Volunteers
- 59 people
- Sponsor
- Asan Medical Center
Breast Neoplasms, Endometrial Neoplasms
Chemotherapy With Whole Body Hyperthermia to Treat Resistant Breast, Endometrial, Cervical and Ovarian Cancers
Thermal therapy (hyperthermia of heat) can increase the effect of chemotherapy treatments. By itself, thermal therapy can also kill cancer cells.
- Conditions
- Breast Neoplasms, Endometrial Neoplasms, Cervix Neoplasms, Ovarian Neoplasms
- Trial name
- NCT00178802
- Testing
- thermochemotherapy (with 5-fluorouracil/interferon-a/liposomal doxorubicin)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase Ib trial studies the best dose and side effects of niraparib and copanlisib in treating patients with endometrial, ovarian, primary peritoneal, or fallopian tube cancer that has come back.
- Conditions
- Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma
- Trial name
- NCT03586661
- Testing
- Copanlisib, Niraparib
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent/Metastatic Endometrial Cancer
Adebrelimab Plus Carboplatin/Paclitaxel Followed by Adebelizumab with or Without Apatinib in the Treatment of Advanced Recurrent/Metastatic Endometrial Cancer (A-CAPE): a Multicenter, Randomized, Controlled, Open-Label Clinical Trial
This study takes investigator-assessed Progression-Free Survival (PFS) as the primary endpoint, with plans to enroll 140 patients with advanced recurrent/metastatic endometrial cancer in a 1:1 ratio, randomized into an…
- Trial name
- A-CAPE (NCT06771154)
- Testing
- Adebelimab Combined with Apatinib, Adebelimab
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Peking Union Medical College Hospital
Recurrent Endometrial Cancer
A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma
Endometrial cancer (EC) is the 8th most common female cancer in Taiwan. Its incidence is increasing in the recent few years, around 1,200 new cases per year.
- Trial name
- NCT01454479
- Testing
- Lapatinib and ixempra
- Volunteers
- 24 people
- Sponsor
- Hung-Hsueh Chou